Related Experiment Videos
Chemokines in transplant rejection.
Christopher A Haskell1, Sofia Ribeiro, Richard Horuk
1Department of Immunology, Berlex Biosciences, Richmond, CA 94804, USA. christopher_haskell@berlex.com
Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
Summary
Chemokines guide leukocytes to transplanted organs, impacting rejection. Targeting chemokine receptors with new therapies may improve transplant survival by selectively suppressing the immune response.
Area of Science:
- Transplant Biology
- Immunology
- Pharmacology
Background:
- Chemokines are crucial mediators of leukocyte migration into transplanted tissues.
- Leukocyte infiltration is a key factor in acute transplant rejection and long-term graft dysfunction.
- Existing immunosuppressive strategies often lack specificity, leading to broad side effects.
Purpose of the Study:
- To review the role of chemokines and their receptors in transplant rejection.
- To discuss current and emerging therapeutic strategies targeting chemokine pathways.
- To highlight the potential for selective immunosuppression in transplantation.
Main Methods:
- Literature review of recent studies on chemokines in transplant biology.
- Analysis of identified chemokine and receptor targets.
- Overview of clinical therapies under investigation.
Main Results:
- Several chemokines and their receptors have been identified as critical targets.
- Therapeutic modulation of chemokine-receptor interactions shows promise in preclinical models.
- Both small molecule inhibitors and biological agents are being developed.
Conclusions:
- Targeting chemokine pathways offers a promising strategy for selective immunosuppression in transplantation.
- These approaches have the potential to improve acute rejection outcomes and long-term graft survival.
- Further clinical investigation is warranted for these novel therapeutic agents.